Rheumatology

An observational cross-sectional study finds that patients suffering from such inflammatory conditions had a higher average number of missing teeth compared to the control group.

The treatment is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and Crohn’s disease.

The new treatment guideline addressed the possibility of differing safety and effectiveness outcomes among patients with rheumatic and musculoskeletal disease regarding vaccination compared with the general population.

The therapy targets both IL-12 and IL-23 cytokines offering a new option for children 6 years and older living with active psoriatic arthritis.

Vitamin D supplements are often recommended for the improvement of bone health, but investigators say the data are unclear whether they prevent fractures.

Patients with high preoperative sleep quality, high preoperative albumin level, free of digestive disease and undergoing total hip arthroplasty procedure are more likely to be discharged within 2 days as opposed to 3.

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

Until now, treatment options for children with lupus nephritis were mostly limited to non-selective immunosuppressants and corticosteroids.

Dr. John Botson explains that gout is not a patient problem, it's a disease problem, and it needs to be approached as a lifelong rheumatic disease as opposed to an episodic one.

Investigator Dr. John Botson spoke on the phase 4 MIRROR study that supported the FDA approval for pegloticase combined with methotrexate for patients with uncontrolled gout.

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

Over a 40-year follow-up, approximately one-quarter of the study cohort with juvenile arthritis were reported to have active uveitis.

Higher energy and longer symptom duration at diagnosis were protective factors against medication failure.

New data suggests that a third COVID-19 booster might be warranted in children with juvenile idiopathic arthritis.

According to preliminary data, patients with JIA experience the same safety and immunogenicity as healthy individuals when vaccinated with the Pfizer COVID-19 vaccine.

Data suggests baricitinib not only significantly reduced the time to flares but also the frequency of flares in patients with JIA when compared with placebo.

A high percentage of pediatric patients with JIA do not achieve inactive disease during the first 2 years following diagnosis.

A new study revealed no significant relationship between patients with juvenile idiopathic arthritis and exposure to maternal infection, however, investigators said that suggestive evidence of differential sex-specific results indicate a need for further study.

Expert Michael Aziz discusses clinical complications that patients face when they become pregnant as well as the importance of medication management and abortion care.

The FDA's decision on the co-treatment of pegloticase plus methotrexate for patients with uncontrolled gout was based on the phase 4 MIRROR clinical trial.

Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.

With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.

The complete ACR manuscript is available to elaborate on the earlier summary of antirheumatic medication for patients who are undergoing total hip or total knee anthroplasty.

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

Rituximab-arrx is similar in safety and efficacy to rituximab for patients with moderate to severe rheumatoid arthritis.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

Dr. Eliseo Pascual's presentation at EULAR 2022 serves as a reminder to consider gender bias during the diagnosis, treatment, and management of rheumatic diseases.

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.